ClinicalTrials.gg
RecruitingNCT07569731FIBR DYSPLASIAUpdated Nov 5, 2026

Fibrous Dysplasia: An Epidemiological and Correlational Evaluation of Multimodal Data

An observational study in Fibrous Dysplasia, Fibrous Dysplasia of Bone and Fibrous Dysplasia/McCune-Albright Syndrome, sponsored by Istituto Ortopedico Rizzoli. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-11-05.

Primary conditionFibrous Dysplasia, PolyostoticRegistry: Fibrous Dysplasia of BoneReclassifiedWhy we changed it
Registry
Fibrous Dysplasia of Bone — the first condition term the registry derived for this study.
ClinicalTrials.gg
Fibrous Dysplasia, Polyostotic
Why
  1. The study's listed conditions name Fibrous Dysplasia, Polyostotic, a narrower term within Fibrous Dysplasia of Bone.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Istituto Ortopedico Rizzoli · Observational

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
200
Sex
All
01

Study summary

Fibrous dysplasia is a benign, pseudotumoral, genetic but non-hereditary condition characterized by the presence of one or more areas of abnormal bone development in which the normal structure is replaced by fibrous tissue. It is an extremely heterogeneous condition, as it can be monostotic, polyostotic, or panostotic, or it may occur within the context of more complex syndromes such as McCune-Albright syndrome (in which polyostotic fibrous dysplasia is associated with café-au-lait spots and precocious puberty) or Mazabraud syndrome (in which intramuscular myxomas are present).

This condition is caused by post-zygotic missense mutations, so it is never hereditary, and the affected individual will constitute a so-called "genetic mosaic," a fact that explains the wide variability in the localization of the pathological areas. The mutations in question occur in a gene (GNAS) located on chromosome 20 (20q13.2-13.3); this gene encodes a G protein with GTPase activity, the function of which is consequently impaired.

The aim of this study is to evaluate in detail the characteristics of the patients, their hospitalizations, and related interventions. Given the rarity of the condition, such investigations are often conducted on very limited datasets. The present study is expected to include over 200 patients, providing a comprehensive picture.

An additional aim is to assess the impact of somatic mutations in the GNAS gene and their impact in terms of clinical manifestations.

02

Conditions studied

  • Fibrous Dysplasia
  • Fibrous Dysplasia of Bone
  • Fibrous Dysplasia/McCune-Albright Syndrome
  • Mazabraud Syndrome

Browse trials for

Keywords

  • Fibrous Dysplasia
  • McCune-Albright Syndrome
  • Mazabraud Syndrome
  • Surgical procedures
  • GNAS
  • Pain
03

In context

Fibrous Dysplasia, Polyostotic Reclassified

23 studies on the registry are indexed under Fibrous Dysplasia, Polyostotic; 5 are open to participants now.

Browse Fibrous Dysplasia, Polyostotic studies →

Lead sponsor

Istituto Ortopedico Rizzoli is the lead sponsor of 305 studies on the registry; 104 are open to participants now.

Compared within Fibrous Dysplasia, Polyostotic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrous Dysplasia of Bone. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All consecutive patients affected by Fibrous Dysplasia, McCune-Albright syndrome and Mazabraud syndrome

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients affected by Fibrous Dysplasia, McCune-Albright syndrome and Mazabraud syndrome (retrospectively included from 2009)
  • Availability of clinical and radiological data collected during their recovery at the IOR
  • Availability of tumor tissue in the biobank in sufficient quantity and quality

Exclusion criteria

Exclusion Criteria:

  • Patients who do not meet the inclusion criteria
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
200 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • All patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome

    All patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome with available clinical, radiological and surgical data

  • Fibrous Dysplasia, McCune-Albright syndrome patients with available tissue sample

    All patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome with an available tissue biospecimens for molecular investigation

06

What researchers measure

Primary outcomes

  1. Description of surgical procedures

    Analyze the correlation between the reason for hospitalization (e.g. pain, fractures, etc.), the resulting type of procedure (categorized surgical procedures), and the patients' characteristics considering age (years), sex (male or female), lesion dimension (in cm).

    Time frame: 4 years

Secondary outcomes

  1. Description of clinical features of Fibrous Dysplasia patients

    Describe natural history of patients affected by Fibrous Dysplasia, McCune-Albright syndorme and Mazabraud syndrome

    Time frame: 4 years

  2. Genotype-phenotype correlation

    Identification of somatic pathogenic variants (described using HGMD) and genotype-phenotype correlation of molecular data with available clinical information

    Time frame: 4 years

  3. Number and types of post-interventions complications and pain

    To analyze the number and types of complications following surgeries (e.g. additional surgery, functional limitations) for fibrous dysplasia and to assess the impact of surgery on long bones in terms of pain (presence/absence)

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, Arundel P, Shaw N, Pos VD, Underhil A, Portero D, Heral L, Heegaard AM, Masi L, Monsell F, Stanton R, Dijkstra PDS, Brandi ML, Chapurlat R, Hamdy NAT, Collins MT. Best practice management guidelines for fibrous dysplasia/McCune-Albright syndrome: a consensus statement from the FD/MAS international consortium. Orphanet J Rare Dis. 2019 Jun 13;14(1):139. doi: 10.1186/s13023-019-1102-9. PubMed 31196103 ↗
  • Stanton RP, Ippolito E, Springfield D, Lindaman L, Wientroub S, Leet A. The surgical management of fibrous dysplasia of bone. Orphanet J Rare Dis. 2012 May 24;7 Suppl 1(Suppl 1):S1. doi: 10.1186/1750-1172-7-S1-S1. Epub 2012 May 24. PubMed 22640754 ↗
  • Majoor BCJ, Traunmueller E, Maurer-Ertl W, Appelman-Dijkstra NM, Fink A, Liegl B, Hamdy NAT, Sander Dijkstra PD, Leithner A. Pain in fibrous dysplasia: relationship with anatomical and clinical features. Acta Orthop. 2019 Aug;90(4):401-405. doi: 10.1080/17453674.2019.1608117. Epub 2019 Apr 30. PubMed 31035847 ↗
  • Cohen MM Jr, Howell RE. Etiology of fibrous dysplasia and McCune-Albright syndrome. Int J Oral Maxillofac Surg. 1999 Oct;28(5):366-71. PubMed 10535539 ↗
  • Weinstein LS, Chen M, Liu J. Gs(alpha) mutations and imprinting defects in human disease. Ann N Y Acad Sci. 2002 Jun;968:173-97. doi: 10.1111/j.1749-6632.2002.tb04335.x. PubMed 12119276 ↗
  • Riminucci M, Saggio I, Robey PG, Bianco P. Fibrous dysplasia as a stem cell disease. J Bone Miner Res. 2006 Dec;21 Suppl 2:P125-31. doi: 10.1359/jbmr.06s224. PubMed 17229001 ↗

Individual participant data

Plan to share: No — The data are not publicly available due to privacy and/or ethical restrictions

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2022 (actual). Primary completion is estimated for Jan 2027, 56 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jun 2026 → Jan 2027 and completion Jun 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2026
First posted
May 6, 2026
StartActual
May 12, 2022
Primary completionEst.
Jan 30, 2027was Jun 2026
CompletionEst.
Jun 30, 2027was Jun 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 30, 2026→Jan 30, 2027
Nov 5, 2026
Study completion
Jun 30, 2026→Jun 30, 2027
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Primary completion Jun 30, 2026→Jan 30, 2027
    Study completion Jun 30, 2026→Jun 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07569731
Responsible party
Luca Sangiorgi (Head of Departement of Rare Skeletal Disorders, Istituto Ortopedico Rizzoli) — Principal investigator
First posted
May 6, 2026
Start date
May 12, 2022
Primary completion
Jan 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Luca Sangiorgi, MD, PhD, MSc
Contact
luca.sangiorgi@ior.it
+390516366342

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion